Testing Sunitinib in Cancer Trials
Author Information
Author(s): Rena Buckstein, R. Meyer, L. Seymour, J. Biagi, H. MacKay, S. Laurie, E. Eisenhauer
Primary Institution: National Cancer Institute of Canada Clinical Trials Group
Hypothesis
Can sunitinib effectively treat various types of cancer through its anti-angiogenic properties?
Conclusion
Sunitinib shows promise in treating multiple cancer types by inhibiting angiogenesis.
Supporting Evidence
- Sunitinib has shown activity in gastrointestinal stromal tumors and renal cell carcinoma.
- In a trial, 40% of patients with metastatic renal cell carcinoma achieved a partial response.
- Sunitinib treatment may have broad-spectrum clinical utility due to its anti-angiogenic effects.
Takeaway
Sunitinib is a medicine that helps stop cancer from growing by blocking the blood vessels that feed it.
Methodology
The study involved four phase II trials testing sunitinib in different cancer types.
Potential Biases
Potential bias due to the non-randomized design of the trials.
Limitations
The trials are non-randomized and non-blinded, which may affect the reliability of the results.
Participant Demographics
Patients with relapsed diffuse large B cell lymphoma, malignant pleural mesothelioma, locally advanced or metastatic cervical cancer, and recurrent ovarian cancer.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website